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Abstract
Mismatch between the uptake and utilization of long-chain fatty acids in the myocardium leads to abnormally high
intracellular fatty acid concentration, which ultimately induces myocardial dysfunction. Stearoyl-Coenzyme A desaturase-1
(SCD1) is a rate-limiting enzyme that converts saturated fatty acids (SFAs) to monounsaturated fatty acids. Previous studies
have shown that SCD1-deficinent mice are protected from insulin resistance and diet-induced obesity; however, the role of
SCD1 in the heart remains to be determined. We examined the expression of SCD1 in obese rat hearts induced by a sucrose-
rich diet for 3 months. We also examined the effect of SCD1 on myocardial energy metabolism and apoptotic cell death in
neonatal rat cardiac myocytes in the presence of SFAs. Here we showed that the expression of SCD1 increases 3.6-fold
without measurable change in the expression of lipogenic genes in the heart of rats fed a high-sucrose diet. Forced SCD1
expression augmented palmitic acid-induced lipid accumulation, but attenuated excess fatty acid oxidation and restored
reduced glucose oxidation. Of importance, SCD1 substantially inhibited SFA-induced caspase 3 activation, ceramide
synthesis, diacylglycerol synthesis, apoptotic cell death, and mitochondrial reactive oxygen species (ROS) generation.
Experiments using SCD1 siRNA confirmed these observations. Furthermore, we showed that exposure of cardiac myocytes
to glucose and insulin induced SCD1 expression. Our results indicate that SCD1 is highly regulated by a metabolic syndrome
component in the heart, and such induction of SCD1 serves to alleviate SFA-induced adverse fatty acid catabolism, and
eventually to prevent SFAs-induced apoptosis.
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Introduction
Obesity and related metabolic diseases such as type 2 diabetes
and metabolic syndrome are occurring in pandemic proportions.
Obesity and diabetes have a propensity for increased circulating
fatty acids that induce a distinct cardiac metabolic phenotype
characterized by increased fatty acid uptake and b-oxidation [1].
Evidence from animal studies demonstrated that excessive fatty
acid supply to the heart that is not accompanied by a parallel
increase in fatty acid oxidation leads to lipotoxic cardiomyopathy
characterized by the accumulation of triglycerides (TGs), cer-
amides and diacylglycerol (DAG), which are associated with
increased myocyte apoptosis, myocardial fibrosis, and contractile
dysfunction [1,2]. In addition, cardiac steatosis, defined as
excessive myocardial TG accumulation in the absence of left
ventricular systolic dysfunction, has been demonstrated by
1H-
magnetic resonance spectroscopy in type 2 diabetes patients [3].
Stearoyl-Coenzyme A desaturase-1 (SCD1) is a rate-limiting
enzyme that converts saturated fatty acids (SFAs) into monoun-
saturated fatty acids (MUFAs), mainly oleate (18:1) and palmi-
toleate (16:1). These represent the major MUFAs of membrane
phospholipids, TGs, and cholesterol esters (CEs) [4]. Previous
studies have shown that SCD1-deficinent mice are lean and are
protected from insulin resistance, hypertriglyceridemia, hepatic
steatosis, and diet-induced and genetically induced obesity [5].
The reduction of plasma TG in SCD1-deficient mice is mediated
largely through increased fatty acid oxidation and reduced fatty
acid synthesis in the liver [6,7]. Furthermore, it has been well
described that SFAs are potent proinflammatory molecules and
increase the expression of a number of inflammatory genes by a
nuclear factor kB (NFkB)-dependent mechanism in adipocytes and
macrophages via Toll-like receptor 4 (TLR4) [8,9,10]. Moreover,
systemic administration of antisense oligonucleotide directed
against SCD1 mRNA efficiently prevents the onset of hepatic
insulin resistance in high-fat-fed rats [11]. These studies imply that
SCD1 is a critical mediator of metabolic syndrome; however,
unexpectedly, the absence of SCD1 either by gene deletion or
antisense oligonucleotide accelerated atherosclerosis in a mouse
model of hyperlipidemia and atherosclerosis on a Western diet
despite relatively reduced plasma TG and increased insulin
sensitivity [12,13]. These adverse effects are likely derived from
increased atherogenic inflammation of the arterial wall due to
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These results suggest that intracellular levels of SFAs and MUFAs
controlled by SCD1 have a distinct impact on cellular function in
a cell-type-dependent manner and SCD1 expression should be
tightly controlled.
In this study, we aimed to determine the role of SCD1 and
inducible stimuli of SCD1 gene expression in the heart. We
employed visceral obese rats fed a high-sucrose (HS) diet as a
model of metabolic syndrome and found a marked increase in
SCD1 expression in the heart. In addition, using adenovirus and
siRNA to alter SCD1 expression in cultured cardiac myocytes, we
found evidence indicating that the induction of SCD1 in the heart
markedly inhibits SFA-induced caspase 3 activation, ceremide
synthesis, DAG synthesis, apoptosis and mitochondrial reactive
oxygen species (ROS) generation, and thus seems to act to prevent
SFA-induced lipotoxic cardiomyopathy.
Results
HS diet induced visceral obesity, but did not affect
cardiac function
As shown in Table 1, the HS diet group was 10% heavier than
the chow-fed group (p,0.05). Total visceral fat weight was 94%
higher in the HS diet group than in the chow group after 3 months
of feeding (Table 1); however, there were no differences in heart
weight or carotid systolic and diastolic pressures between the two
groups. Furthermore, echocardiographic parameters, such as left
ventricular wall thickness and left ventricular functional para-
meters (EF, FS, E/A ratio) were not statistically different between
two groups (Table 1). These data indicate that the 3-month HS
diet induced severe visceral obesity but abnormalities of the
cardiac structure and function were not apparent.
HS diet induced SCD1 mRNA expressions in rat hearts
To determine the effects of HS diet on the expression of SCD1
in rat hearts, SCD1 mRNA expression was determined by semi-
quantitative or real-time RT-PCR after 3 months of feeding. As
shown in Figure 1A and B, SCD1 mRNA was significantly
increased after HS feeding (2.060.4 fold. vs control. n=6,
*p,0.05). In contrast, expression levels of other lipid biosynthesis
genes or FA oxidative genes were similar between control and HS
diet groups (Figure 1C) at the same time point. Therefore, SCD1
was specifically induced in HS-fed rat hearts.
HS diet or obesity induced SCD1 protein expression in rat
and human hearts
Analysis of histological change with hematoxylin and eosin (HE)
or Masson’s trichrome staining did not reveal differences in
morphology between control and HS diet groups (Figure 1D–G).
To determine the cellular location of SCD1 proteins in rat hearts,
we performed immunohistochemical staining of ventricular
sections with anti-SCD1 antibodies after 3 months of feeding.
While minimal SCD1 staining was observed in the control hearts
(Figure 1H), SCD1 was clearly stained in the cytoplasm of HS diet
rat hearts after 3 months of feeding (Figure 1I). Furthermore, we
examined the human hearts obtained by autopsy. The expression
of SCD1 appears to be more abundant in the hearts of diabetic
patients than in those from lean subjects and non-diabetics
(Figure 1J and K). These observations suggest that the myocardial
expression of SCD1 increases in obesity.
HS diet increased plasma glucose, insulin and FFAs levels,
and plasma/tissue SCD1 activity
Plasma glucose levels, insulin levels and HOMA-IR were higher
in rats fed the HS diet than rats fed the normal diet (Table 2).
Plasma FFA levels also increased in the HS diet group. In contrast,
other lipid parameters, such as HDL cholesterol, LDL cholesterol,
total cholesterol and TG, were comparable between the two
groups. Furthermore, analysis of plasma and heart tissue FFA
composition showed that the percentage of MUFAs, such as
palmitoleic acid or oleic acid, was markedly increased, while that
of stearic acid, an SFA, was decreased (% by weight, Table 3, 4).
From these FFA composition analyses, the ratio of oleic acid (18:1
v9) to stearic acid (18:0) was also significantly increased in rat
hearts with HS diet compared to control animals (Table 3,4).
These results proved that HS diet increased SCD1 activity in rat
hearts as well as plasma SCD1 activity. In addition, TG content in
the hearts was significantly increased after HS feeding in
comparison with control rat hearts (1.7060.05 vs.
1.3760.05 mg/g tissue, n=4, p,0.05). These results are
consistent with the increased expression of SCD1 in rats fed the
HS diet.
Glucose, insulin, and saturated FAs induced SCD1
expression in cardiac myocytes
To determine the pathogenic factors contributing to the
increase in SCD1 expression in the heart, neonatal rat cardiac
myocytes were incubated with glucose, insulin, SFAs or MUFAs.
SCD1 mRNA expression was increased by glucose or insulin in a
dose-dependent manner (Figure 2A and B). Furthermore, SFAs,
palmitic acid or stearic acid induced SCD1 mRNA expression. In
contrast, MUFAs, oleic acid or linoleic acid didn’t affect the
expression of SCD1 (Figure 2C). These results are consistent with
our in vivo data indicating that an induction of SCD1 mRNA in
the heart was associated with an increase in plasma glucose, insulin
and FFAs levels in obese rats.
Table 1. Biometric and echocardiographic parameters of rats
fed the control or HS diet.
Control High sucrose
Physical measurements
Body weight (g) 438.5647.5 486.0631.7*
Heart weight (g) 0.8860.08 0.9460.06
SBP (mmHg) 100.1620.8 99.0611.7
DBP (mmHg) 76.1624.6 66.6615.5
Visceral Fat (g) 15.963.2 31.063.9**
Echocardiogram
IVSd (mm) 1.760.3 1.860.3
LVEdD (mm) 8.360.6 7.760.9
LVPWd (mm) 1.760.2 1.960.3
LVEsD (mm) 5.160.6 4.561.1
EF (%) 74.166.9 76.968.4
FS (%) 38.965.5 41.869.1
E/A 2.060.2 2.160.6
Data are the means 6 SD.
*P,0.05, **P,0.01 vs. control fed group.
SBP, systolic blood pressure; DBP, diastolic blood pressure; IVSd, Interventricular
septal end-diastolic dimension; LVEdD or LVEsD, left ventricular end-diastolic or
systolic diameter; LVPWd, left ventricular posterior wall thickness in diastole; EF,
ejection fraction; FS, fractional shortening; E/A, transmitral flow ratio.
doi:10.1371/journal.pone.0033283.t001
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accumulation, and suppressed saturated FA-induced
excessive FA oxidation
To determine the effects of SCD1 on fatty acid homeostasis in
cardiac myocytes, we prepared SCD1-overexpressing cardiac
myocytes using adenovirus. Palmitic acid was used as a substrate
of SCD1. As shown in Figure 3, adenovirus-mediated SCD1
overexpression markedly induced lipid accumulation by the
addition of palmitic acid compared with Ad-LacZ-transduced
cells. We next examined the effects of SCD1 on the oxidation of
FA and glucose in cardiac myocytes. Consistent with the previous
report, palmitic acid markedly increased FA oxidation and
decreased glucose oxidation in the absence of SCD1 overexpres-
sion (Figure 4A and B). Interestingly, as shown in Figure 4C and
D, the overexpression of SCD1 significantly attenuated palmitic
acid-induced FA oxidation, and restored palmitic acid-induced
Figure 1. Expression of SCD1 in HS diet rat hearts and in obese and diabetes patients’ hearts. (A) and (B): Semi-quantitative RT-PCR (A)
and real-time RT-PCR (B) showed the increased expression of SCD1 after 3 months in HS diet rat hearts in comparison with normal fed rat hearts.
GAPDH was measured as an internal control. mRNA of the normal fed group was normalized to a value of 1, and the mRNA level in the HS-fed group
is shown relative to the control level. Values are reported as the means 6 SD. N=6–8, **p,0.01 vs. control. (C): Semi-quantitative RT-PCR of SCD1,
lipoprotein lipase (LPL), fatty acid synthase (FAS), acyl-CoA synthase (ACS), elongation of long chain fatty acid member 6 (Elovl6), peroxisome
proliferator coactivator-1a (PGC-1a), peroxisome proliferator-activated receptor a (PPARa), pyruvate dehydrogenase kinase isozyme 1 and 4 (PDK1,
PDK4) in HS- or normal fed rat hearts after 3 months. Expression levels of other lipid biosynthesis genes or FA oxidative genes were similar between
two groups at the same time point. (D) to (G): Pathology of SCD1 in HS- or normal fed rat heart. HE-stained sections (D) and (E) and Masson’s
trichrome staining (F) and (G) of rat myocardium after 3 months of feeding. (D), (F): Normal fed; (E), (G): High-sucrose fed. (H) and (I):
Immunohistochemical staining showed increased expression of SCD1 after 3 months in HS-fed rat hearts (I), while minimal SCD1 staining was
observed in control hearts (H). (J) and (K): Although SCD1 was not detectable in cardiac myocytes of normal healthy subject (J) using
immunohistochemical staining, SCD1 expression was increased in obese and diabetes patients’ hearts (K). Counterstaining was performed with 2%
methyl green. Scale bar=200 mm.
doi:10.1371/journal.pone.0033283.g001
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elevated SCD1 expression ameliorates SFA-induced excessive
energy reliance on FA.
Because b-FA oxidation is stimulated by AMP-activated protein
kinase (AMPK), we examined whether the inhibition of palmitic
acid-induced FA b-oxidation in SCD1 overexpression is mediated
by the suppression of AMPK activity. In addition, we examined
the phosphorylation of acetyl-CoA carboxylase beta (ACCb)a t
Ser-79, which leads to inactivation of ACC activity and decreases
malonyl-CoA synthesis. Because malonyl-CoA strongly inhibits
the activity of CPT-I, which plays a key role in controlling the rate
of FA uptake by mitochondria, AMPK activation and subsequent
ACCb-phosphorylation result in the acceleration of fatty acid
oxidation. The results showed that SCD1 overexpression de-
creased the phosphorylation of AMPK and ACCb in the absence
or presence of an AMPK-activating agent, oligomycin (Figure 4E).
Therefore, we assumed that attenuation of SFA-induced up-
regulation of FA oxidation is mediated at least partly through the
inhibition of AMPK activity and the resultant increased ACC
activity.
SCD1 attenuated saturated FA-induced apoptosis in
cardiac myocytes
We next examined whether SCD1 regulates saturated FA-
induced apoptosis. As shown in Figure 5A–C, palmitic acid or
stearic acid increased the activated caspase 3 protein level, caspase
3 and 7 activities, and TUNEL-positive stained cells. In contrast,
SCD1 overexpression significantly attenuated saturated FA-
induced apoptotic changes. To determine the mechanisms by
which SCD1 mediates the modification of saturated FA-induced
Table 2. Plasma parameters of rats fed the control or HS diet
for 3 months.
Control High sucrose
HDL (mg/dl) 24.665.4 24.463.1
LDL (mg/dl) 4.461.8 3.760.8
Total cholesterol (mM/l) 1.460.4 1.360.2
Triglyceride (mg/dl) 20.7621.6 50.7661.0
Free fatty acid (mEq/l) 576.46344.2 2241.86869.3**
Glucose (mg/dl) 167.2633.6 176.7622.2**
Insulin (ng/ml) 3.662.5 11.364.9**
Data are the means 6SD. **P,0.01 vs. control fed group.
**HDL: high density lipoprotein, LDL: low density lipoprotein.
doi:10.1371/journal.pone.0033283.t002
Table 3. Plasma fatty acid composition of rats fed the control
or HS diet for 3 months.
Control High-sucrose
Lauric acid (C12:0) 0.060.0 0.060.0
Myristic acid (C14:0) 0.360.1 0.660.1*
Myristoleic acid (C14:1 v5) ,0.01 ,0.01
Palmitic acid (C16:0) 23.261.3 24.660.8
Palitoleic acid (C16:1 v7) 2.060.2 6.962.3*
Stearic acid (C18:0) 10.960.2 7.961.6**
Oleic acid (C18:1 v9) 9.660.7 18.762.9**
Linoleic acid (C18:2 v6) 17.561.3 13.661.4**
c-linolenic acid (C18:3 v6) 0.460.1 0.360.0
Linolenic acid (C18:3 v3) 0.360.1 0.360.0
Arachic acid (C20:0) 0.160.0 0.160.0
Eicosenoic acid (C20:1 v9) 0.160.0 0.260.0*
Eicosadienoic acid (C20:2 v6) 0.160.0 0.260.0*
5-8-11eicosatrienoic acid (C20:3 v9) 0.160.0 0.560.1*
Dihomo-c-linolenic acid (C20:3 v6) 0.660.1 1.260.2**
Arachidonic acid (C20:4 v6) 27.562.5 17.465.9*
Eicosapentaenoic acid (C20:5 v3) 0.660.1 1.060.4
Behenic acid (C22:0) 0.360.0 0.360.0*
Erucic acid (C22:1 v9) ,0.01 ,0.01
Docosatetraenoic acid (C22:4 v6) 0.360.0 0.260.0
Docosapentaenoic acid (C22:5 v3) 0.660.1 0.660.2
Lignoceric acid (C24:0) 0.860.1 0.660.1*
Docosaphexaenoic acid (C22:6 v3) 4.260.4 4.360.2
Nervonic acid (C24:1 v9) 0.660.1 0.660.1
SCD1 activity (18:1 v9/18:0) 0.960.1 2.560.8**
Data are the means 6SD, and are presented as percent of total fatty acids.
*P,0.05, **P,0.01 vs. control fed group.
doi:10.1371/journal.pone.0033283.t003
Table 4. Heart tissue fatty acid composition of rats fed the
control or HS diet for 3 months.
Control High-sucrose
Lauric acid (C12:0) 0.060.0 0.060.0
Myristic acid (C14:0) 0.160.0 0.360.1*
Myristoleic acid (C14:1 v5) ,0.01 ,0.01
Palmitic acid (C16:0) 13.261.1 14.861.0
Palitoleic acid (C16:1 v7) 0.460.1 1.760.5**
Stearic acid (C18:0) 20.260.8 18.061.1*
Oleic acid (C18:1 v9) 4.860.7 7.661.4**
Linoleic acid (C18:2 v6) 24.861.2 24.262.1
c-linolenic acid (C18:3 v6) 0.260.0 0.160.0*
Linolenic acid (C18:3 v3) 0.260.0 0.160.0
Arachic acid (C20:0) 0.360.1 0.360.0
Eicosenoic acid (C20:1 v9) 0.160.0 0.160.0
Eicosadienoic acid (C20:2 v6) 0.260.0 0.160.0*
5-8-11eicosatrienoic acid (C20:3 v9) ,0.01 0.160.0
Dihomo-c-linolenic acid (C20:3 v6) 0.460.0 0.660.1**
Arachidonic acid (C20:4 v6) 19.361.1 17.961.2
Eicosapentaenoic acid (C20:5 v3) 0.260.0 0.260.0
Behenic acid (C22:0) 0.360.1 0.260.0
Erucic acid (C22:1 v9) ,0.01 ,0.01
Docosatetraenoic acid (C22:4 v6) 0.760.1 0.660.0
Docosapentaenoic acid (C22:5 v3) 2.060.3 1.860.2
Lignoceric acid (C24:0) 0.360.0 0.360.0
Docosaphexaenoic acid (C22:6 v3) 12.261.2 10.761.3
Nervonic acid (C24:1 v9) 0.160.0 0.160.0
SCD1 activity (18:1 v9/18:0) 0.260.0 0.460.1*
Data are the means 6SD, and are presented as percent of total fatty acids.
*P,0.05, **P,0.01 vs. control fed group.
doi:10.1371/journal.pone.0033283.t004
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cardiac myocytes transduced with Ad-LacZ or Ad-SCD1 by the
addition of saturated FAs. Both DAG and ceramide levels were
markedly induced by stimulation with palmitic acid or stearic acid,
while these effects were blunted by SCD1 overexpression using
Ad-SCD1 (Figure 5D and E). These results suggest that SCD1
suppressed saturated FA-induced DAG and ceramide production
in cardiac myocytes.
To confirm the suppressive effects of SCD1 on saturated FA-
induced apoptosis, we studied the effects of loss of function of
SCD1 using siRNA transfection in cardiac myocytes. As expected,
FA induced-apoptotic changes, such as the caspase 3 level, caspase
activity, and TUNEL-positive cells, were augmented by knock-
down of SCD1 (Figure 6A–C). These findings suggest that SCD1
had protective effects against saturated FA-induced apoptosis in
cardiac myocytes.
SCD1 modulated saturated FA-induced ROS levels in
cardiac myocytes
To assess the protective effects of SCD1 on mitochondrial
function from saturated FA toxicity in cardiac myocytes, we tested
mitochondrial ROS levels induced by PA or SA in cardiac
myocytes. Cardiac mycytes were infected with Ad-LacZ or Ad-
SCD1, transfected with siGFP or siSCD1 in the presence or
absence of PA or SA; ROS levels were detected in the treated cells.
As shown in Figure 7A, Ad-LacZ infection alone had minimal
effects on basal ROS levels. PA and SA significantly increased
intracellular ROS levels in cardiac myocytes transduced with Ad-
LacZ, an observation consistent with previous reports [14]. These
ROS levels were markedly reduced by adenovirus-mediated
SCD1 overexpression. In contrast, suppression of SCD1 by
specific siRNA not only increased basal ROS levels, but also
augmented the PA or SA–induced increase in ROS levels
(Figure 7B). These data suggest that SCD1 expression was closely
related to protection of mitochondria from PA and SA-induced
toxicity.
High dose of hydrogen peroxide decreased SCD1 mRNA
expression in cardiac myocytes
These results of in vivo and in vitro experiments led us to propose
a new model in which SCD1 exerts a protective effect against
saturated FAs-induced cardiac lipotoxicity. We next tried to
identify factors that regulate SCD1 gene expressions in cardiac
myocytes. Isolated cardiac myocytes were incubated with various
reagents which are relevant to oxidative stress, such as angiotensin
II, endothelin-1, norepinephrine, lipopolysaccharide, hypoxia, and
hydrogen peroxide. Real-time PCR revealed that all of the
reagents tested significantly increased SCD1 mRNA expression
(Figure 8A and B). Low dose (0.1–1 mM) of hydrogen peroxide, an
analog of oxidative stress, also significantly increased SCD1
mRNA expression in cardiac myocytes, however, high dose (10–
50 mM) of hydrogen peroxide markedly decreased SCD1 mRNA
expression (Figure 8C). Thus, the strong oxidative stress induced
by such as a high dose of hydrogen peroxide may inhibit SCD1
expression in cardiac myocytes.
Discussion
The major findings in this study are five-fold. First, we provide
evidence that SCD1 expression and activity are markedly induced
in the heart of obese diabetic rats fed an HS diet. Second, by in
vitro experiments using an adenovirus- or siRNA-mediated
approach, we show that SCD1 plays a role in attenuating palmitic
acid-induced excessive fatty acid oxidation and caspase 3
activation that leads to apoptosis in neonatal rat cardiac myocytes.
Third, SCD1 overexpression inhibits palmitic acid-induced de
novo synthesis of ceramide and DAG. Fourth, SCD1 attenuates
palmitic acid-induced mitochondrial ROS generation in cardiac
myocytes. Fifth, SCD1 expression in cardiac myocytes is highly
sensitive to a number of dietary, hormonal, and environmental
factors. Interestingly, hydrogen peroxide, an inducer of oxidative
stress, has the positive or negative effect on SCD1 expression
depending on its concentration similar to a previous report [15].
Collectively, these findings suggest that the induction of SCD1
expression in the heart serves to protect the cells from the
unfavorable effects of elevated SFAs, which cause lipotoxic
cardiomyopathy.
SCD1 is a highly regulated gene in the heart
We found that SCD1 mRNA levels most markedly increased in
the heart by the HS diet. Among the many genes involved in
Figure 2. Effect of glucose, insulin and FFAs on SCD1 mRNA
expression in neonatal rat cardiac myocytes. (A) to (C): Real-time
RT-PCR showed that SCD1 expressions were increased in neonatal rat
cardiac myocytes which treated with (A) glucose (100 to 450 mg/dl), (B)
insulin (1 to 10 mM), and (C) saturated FAs, palmitic acid (PA) or stearic
acid (SA) for 24 h. On the other hand, unsaturated FAs, oleic acid (OA)
or linoleic acid (LA) didn’t affect the expression of SCD1.
doi:10.1371/journal.pone.0033283.g002
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heart because the expression of other genes examined, such as LPL,
FAS, and ACS genes, was not measurably affected. Notably, the
expression of PPARa,P G C - 1 a and PGC-1b, inducible nuclear
receptor and its coactivators, which regulate the genes encoding
enzymesateverylevelofoxidativeenergymetabolismincludingfatty
acid uptake and mitochondrial b-oxidation [16,17], was not induced
by the HS diet. Although we did not address the rationale for this
differential regulation among lipogenic genes by the HS diet, we
assume that in the heart, HS diet preferentially enhances the
pathway that leads to fatty acid storage as TG or CE rather than
fatty acid synthesis, given that SCD1 catalyzes the biosynthesis of
MUFAs from SFAs, and MUFAs serve as the preferred substrate for
the synthesis of storage lipids, TG and CE [18].
Is SCD1 in the heart a friend or foe?
Our findings that SCD1 overexpression reduced SFA-induced
apoptosis, and that siRNA for SCD1 abolished this protective
effect allowed us to hypothesize that SCD1 induction is beneficial
rather than detrimental to the heart. As illustrated in Figure 9,
elevated plasma FA, glucose and insulin increased SCD1
expression in cardiac myocytes. Increased expression of SCD1,
in turn, might protect from palmitic acid-induced excessive fatty
acid oxidation and apoptosis through mechanisms involving
down-regulation of the AMPK/ACC-pathway, inhibition of
ceramide and DAG synthesis, and inhibition of mitochondrial
ROS generation. Furthermore, mild oxidative stress may stimulate
SCD1 expression. We suggest that this period is an adaptive stage.
On the other hand, SCD1 expression is reduced when oxidative
stress is increased. In this condition, SFAs are no longer converted
to MUFAs, and ceramide synthesis increases and, as a conse-
quence, strong oxidative stress contributes to the onset of lipotoxic
cardiomyopathy. Thus, we propose this as a maladaptive stage.
This concept is clearly contradictory to previous reports, which
showed that SCD1 deficiency in the liver and adipose tissue [19]
as well as in the whole body results in a marked beneficial
metabolic outcome, including increased energy expenditure,
reduced body adiposity and increased insulin sensitivity [6,7]. In
addition, Hulver et al. demonstrated that SCD1 gene expression is
up-regulated in skeletal muscle from extremely obese humans [20].
They showed that elevated SCD1 expression increased TG
synthesis and MUFAs in skeletal muscle because overexpression
of SCD1 in cultured primary skeletal muscle cells from lean
subjects produced a metabolic phenotype resembling that
displayed by myocytes from obese subjects; increased TG synthesis
and decreased fatty acid oxidation. Inhibition of SCD activity has
been proposed as a therapeutic strategy for the treatment of
obesity, diabetes, liver steatosis and metabolic syndrome [21];
however, the ability of SCD1 to prevent SFA-induced apoptosis of
cardiac myocytes suggests that SCD1 in the heart is a potential
target that should be activated, at least in the short term, for the
prevention of apoptosis.
Effects of SCD1 on palmitic acid-induced fatty acid
oxidation and glucose oxidation in the heart
We envisage several mechanisms through which SCD1
overexpression attenuates palmitic acid-induced fatty oxidation.
First, SCD1 channels palmitic acid toward the storage of TG and
away from b-oxidation, as demonstrated by previous studies using
SCD1-overexpressing CHO cells and primary skeletal muscle
[20,22,23]. In those studies, MUFAs but not SFAs are readily
incorporated into TG while SFAs do not lead to TG accumula-
tion. Second, we found that SCD1 overexpression decreased the
phosphorylation of AMPK. Consistent with the results of this
study, inhibition of AMPK phosphorylation by SCD1 has been
described [20]. In that study, SCD1 overexpression in primary
human skeletal muscle cells decreased fatty acid oxidation by 45%
and reduced AMPK and ACC activity. Furthermore, SCD1
deficiency activated AMPK in the liver and skeletal muscle but not
in the heart [24,25,26]. Further studies are necessary to determine
the mechanisms by which SCD1 controls AMPK activity in the
heart.
We found that exogenous palmitic acid reduces glucose
oxidation concomitantly with the increase in fatty acid oxidation.
The most plausible explanation for this shift of substrate
preference would be that referred to as the ‘‘Randle cycle’’ or
‘‘glucose-fatty acid cycle’’ [27]. To date, the Randle cycle has been
interpreted to be largely due to the activation of pyruvate
dehydrogenase kinase 4 (PDK4) and subsequent phosphorylation
Figure 3. Involvement of SCD1 and lipid accumulation in cardiac myocyte. (A) to (F): Neonatal rat cardiac myocytes were infected with Ad-
LacZ or Ad-SCD1 at a multiplicity of infection of 20. Oil red O staining showed that TG accumulation was markedly increased in myocytes transduced
with Ad-SCD1 (D to F) in comparison with cells transduced with Ad-LacZ (A to C). 100 mM (B and E) or 250 mM (C and F) addition of palmitic acid (PA)
was used as a substrate of SCD1, and BSA was used as a vehicle. Scale bar=100 mm.
doi:10.1371/journal.pone.0033283.g003
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rate of FA oxidation [28,29]. In this regard, the mechanism by
which SCD1 overexpression restored the PA-induced decrease in
glucose oxidation would be secondary to the decrease in FA
oxidation. Because the PDK4 gene promoter contains a
PPARa-response element (PRE) [30], activation of PPARa/
PGC-1a complex by fatty acid ligand may play a role. This
hypothesis is currently under investigation.
AretheeffectsofSCD1oncellularfunctioncell-typespecific?
In agreement with our data, the beneficial metabolic effects
of SCD1 induction have been demonstrated in human primary
arterial endothelial cells, skeletal muscle cells and pancreatic beta-
cells [23,31,32]. These studies showed that SCD1 induction
either by liver X receptor (LXR) activator TO-901317 or by
palmitic acid contribute to improved insulin sensitivity, reduced
endoplasmic reticulum (ER) stress and reduced inflammatory
response while SCD1 induction is associated with increased
intracellular lipid accumulation. In contrast, SCD1 deficiency has
been shown to reduce ceramide synthesis in skeletal muscle and
attenuates inflammation in white adipose tissue [25,33].
In conclusion, this study shows that SCD1 in the heart is highly
induced by an HS diet in vivo and by a variety of molecules
relevant to metabolic syndrome in cardiac myocytes in vitro. Our
Figure 4. FA and glucose oxidations in SCD1-overexpressed cardiac myocytes. (A): FA oxidation was significantly increased in rat neonatal
cardiac myocytes treated with 100 mM palmitic acid (PA). (B): On the other hand, glucose oxidation was significantly reduced in cardiac myocytes
treated with PA (100 mM). (C): PA (50 to 100 mM) induced excessive FA oxidation was attenuated in cardiac myocytes transduced with a MOI of 20 of
Ad-SCD1 (&) in comparison with control cells transduced with Ad-LacZ (%). (D): PA (50 to 100 mM) -induced suppression of glucose oxidation
recovered in cardiac myocytes transduced with Ad-SCD1 (&) in comparison with control cells transduced with Ad-LacZ (%). BSA was used as a
vehicle. Each sample was counted in a scintillation counter (cpm) and data are shown as the mean 6 SD. **P,0.01 vs. Ad-LacZ in each PA
concentration. (E); Phosphorylation levels of AMPK and ACC decreased in cardiac myocytes transduced with an MOI of 20 of Ad-SCD1 in comparison
with control cells transduced with Ad-LacZ. Oligomycin (1 mM) was used as an AMPK and ACC activator.
doi:10.1371/journal.pone.0033283.g004
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acid-induced fatty acid oxidation, caspase 3 activation, apoptosis
and mitochondrial ROS generation. These effects are associated
with the accumulation of TG. These results presented here clearly
argue against the concept that loss of SCD1 improves cardiac
metabolism directly or indirectly through combating metabolic
syndrome, and raise the intriguing possibility that SCD1 plays a
distinct role in a cell type-dependent and a nutritional status-
dependent manner.
Materials and Methods
Animals and treatments
Obesity and diabetes model rats were prepared as described
previously [34]. Briefly, 6-week-old male Wistar rats (250–300 g)
were divided into two groups of 6–8 rats: the control group was fed
standard chow (MF: 81% carbohydrates, 13% protein, and 6% fat;
Oriental Yeast Co., Tokyo, Japan), and the HS diet group was fed
sucrose-rich chow (50% sucrose and 50% standard chow). All
Figure 5. Saturated FA-induced apoptosis, DAG and ceramide level in SCD1-overexpressed cardiac myocytes. Cardiac myocytes were
infected with Ad-LacZ as a control or Ad-SCD1 at an MOI of 20, and simultaneously treated with palmitic acid (PA) or stearic acid (SA). (A): Cleaved-
caspase 3 and caspase 3 protein levels were analyzed by Western blotting. 250 mM of PA or SA induced cleaved-caspase 3 levels, and these
inductions were attenuated in myocytes transduced with Ad-SCD1. (B): Caspase 3 and 7 activities were increased with PA or SA (100 to 250 mM) in
cardiac myocytes, and inhibited in cells transduced with Ad-SCD1 (&) in comparison with control cells transduced with Ad-LacZ(%). Values are
shown as the mean 6 SD. **P,0.01 vs. Ad-LacZ in each PA or SA concentration. (C): To detect cell death via DNA fragmentation, left panels illustrate
TUNEL fluorescent staining (green) and right panel illustrates nuclei (DAPI: blue). Scale bar=200 mm. 250 mM of PA or SA induced TUNEL-positive cells
in neonatal rat cardiac myocytes transduced with Ad-LacZ, and these TUNEL-positive cells were reduced by Ad-SCD1 transduction. (D) and (E): Both
(D) DAG and (E) ceramide levels in lipid extracts were significantly increased by the addition of PA or SA (250 mM), and these increases of DAG and
ceramide were attenuated in myocytes transduced with Ad-SCD1 (&) in comparison with control cells transduced with Ad-LacZ (%). Each sample
was counted in a scintillation counter (cpm). An arbitrary value of 1.0 was assigned to cells transduced with Ad-LacZ by the addition of BSA. Data are
shown as the mean 6 SD. **P,0.01 vs. Ad-LacZ in each PA or SA concentration.
doi:10.1371/journal.pone.0033283.g005
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weeks in climate controlled metabolic cages with a 12-h light/12-h
d a r kc y c le ,a n dfo o d(a ss p e c if i e da b o v e )a n dw a t e rp r o v i d e dadlibitum.
All experiments using these rats were approved by and performed
according to the guidelines of the Animal Ethics Committee of
Gunma University, Maebashi, Japan (Permit Number: 07-101).
Hemodynamic measurements and echocardiographic
evaluation
Ascending aortic pressure and heart rate were measured in the
unrestricted, conscious state through a heparinized indwelling
polyethylene catheter that was introduced into the left carotid
artery 1 day before measurement. Data were analyzed using
Figure 6. Saturated FA-induced apoptosis in cardiac myocytes with loss of SCD1 function using siRNA transfection. Cardiac myocytes
were transfected with siGFP as a control or siSCD1 at 20 mM, and simultaneously treated with palmitic acid (PA) or stearic acid (SA). (A): Loss of SCD1
function (siSCD1) augmented cleaved-caspase 3 levels induced by 250 mM of PA or SA. (B): Caspase 3 and 7 activities induced by PA or SA (100 to
250 mM) in cardiac myocytes were also augmented by the loss of SCD1 function (siSCD1: &) in comparison with control cells transduced with siGFP
(%). Values are shown as the mean 6 SD. *P,0.05 or **P,0.01 vs. siGFP in each PA or SA concentration. (C): 250 mM of PA or SA induced TUNEL-
positive cells in neonatal rat cardiac myocytes transduced with siGFP, and these TUNEL-positive cells increased by the loss of SCD1 function (siSCD1).
Scale bar=200 mm.
doi:10.1371/journal.pone.0033283.g006
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Australia). Blood was collected after hemodynamic measurement
and blood plasma was separated immediately by centrifuging at
1500 rpm for 20 min at 4uC. Left ventricular wall thickness and
function were measured by echocardiography (EUB6000; Hitachi,
Tokyo, Japan) using a 10-MHz probe. Before feeding and after 12
weeks of feeding, rats were anesthetized with ketamine (50 mg/kg)
and xylazine (10 mg/kg) injected intraperitoneally and subjected
to echocardiographic study. Left ventricular ejection fraction
(EF, %), fractional shortening (FS, %) and the ratio of the early to
late filling wave (E/A) of the transmitral pulse-wave Doppler
velocity were measured as described previously.
Tissue preparation and total RNA extraction
Following the induction of deep anesthesia, rats were killed and the
hearts were excised immediately. Left ventricles were frozen rapidly
in liquid nitrogen and stored at 270uC until real-time quantitative
RT-PCR analysis. In addition, tissue blocks from hearts were fixed in
4% paraformaldehyde for 4 to 12 h, embedded in paraffin, and
sectioned at 4-mm thickness for immunohistochemistry.
RNA extraction and Real-Time Reverse Transcription (RT)-PCR
Total RNA was prepared from the heart using Isogen (Wako,
Tokyo, Japan) according to the manufacturer’s protocol. One
microgram of RNA was used for reverse transcription with the
RNA LA PCR Kit (TAKARA BIO, Shiga, Japan) and real-time
RT-PCR analysis was performed using SYBR Green Real-time
PCR Master Mix-Plus (TOYOBO, Osaka, Japan) according to the
manufacturers’ protocol. Primer sequences were as follows: rat
SCD1-sense, 59- CCTCATCATTGCCAACACCAT -39; anti-
sense, AGCCAACCCACGTGAGAGAA -39. Specificity of the
SYBR Green amplicons was confirmed by melting point analysis
and gel electrophoresis in the presence of ethidium bromide
(Nippon Gene, Tokyo, Japan). Expression of the housekeeping
gene GAPDH was used for normalization.
Immunohistochemistry
Human heart tissues were obtained from patients at autopsy
with informed consent of their family at Gunma University
Hospital. This protocol was approved by the Institutional Review
Board at Gunma University Hospital. Tissue samples were fixed in
Figure 7. SCD1 modulated saturated FA-induced ROS levels in cardiac myocytes. Cardiac myocytes were (A) infected with Ad-LacZ as a
control or Ad-SCD1 at an MOI of 20 or (B) transfected with siGFP as a control or siSCD1 at 20 mM, and simultaneously treated with palmitic acid (PA,
250 mM) or stearic acid (SA, 250 mM). Intracellular ROS levels were detected with CM-H2DCFDA. PA or SA-induced ROS levels in neonatal rat cardiac
myocytes transduced with Ad-LacZ, and these ROS levels were reduced by Ad-SCD1 transduction. In contrast, knockdown of SCD1 by siRNA
increased basal ROS levels, and enhanced PA or SA-induced ROS levels. Scale bar=200 mm.
doi:10.1371/journal.pone.0033283.g007
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histochemical staining was performed using a DAKO Catalyzed
Signal Amplification (CSA) system (DAKO, Glostrup, Denmark),
according to the manufacturer’s instructions. Tissue cross sections
(4 mm) including the left ventricle and interventricular septum
were stained with rabbit monoclonal anti-SCD1 (C12H5)
antibody (Cell Signaling Technology, MA, USA) at dilutions of
1:200 in Can Get Signal immunostaining solution A overnight at
4uC. Counterstaining was performed with 2% methyl green.
Negative controls were produced by substituting non-immune
mouse immunoglobulin (DAKO) for the primary antibody.
Measurements of plasma and heart tissue parameters
Plasma total cholesterol, HDL cholesterol, LDL cholesterol,
TG, free fatty acid (FFA), glucose and insulin were determined by
enzymatic, colorimetric assays by an external laboratory (SRL
Inc., Tokyo, Japan). Tissue lipids were extracted using the method
of Bligh and Dyer [35] and expressed as counts per minute in the
whole organ. Fatty acid composition analysis in plasma and heart
tissue was also performed by SRL Inc. The compositions were
expressed as the concentration (mg/mL of plasma) and percentage
by weight of total fatty acids. TG content in the heart was
measured using TG-E Test Wako (Wako) according to the
manufacturer’s protocol.
Preparation of neonatal rat cardiac myocytes
Primary neonatal rat cardiac myocyte cultures were prepared as
previously described [36]. Using this method, we routinely
obtained cardiac myocyte-rich cultures with .95% of the cells
being cardiac myocytes, as assessed by immunocytochemical
staining with monoclonal antibody against sarcomeric a-actinin
(Sigma-Aldrich, MO, USA).
Serum-starved (24 h) cardiac myocytes were incubated in the
presence or absence of glucose (100 to 450 mg/dl), insulin (1 to
10 mM), fatty acid-free BSA (Sigma-Aldrich)-conjugated palmitic
acid, stearic acid, oleic acid and linoleic acid (each 100 mM,
Sigma). Fatty acid composition adjusted for the HS diet group’s
parameters, was also stimulated (100 to 500 mM). After 24 h
incubation at 37uC, mRNA was collected from the cells.
Generation of Recombinant Adenovirus
Adenoviruses expressing LacZ (Ad-LacZ) or SCD1 (Ad-SCD1)
were generated as described previously [37]. Cardiac myocytes
were infected with Ad-SCD1 or Ad-LacZ at a multiplicity of
infection of 20 for 48 h in preparation for the next experiment.
Construction of siRNA oligonucleotide and transfection -siRNA oligo-
nucleotides (siSCD1: CCU UCU UGA GAU ACA CUC UGG,
siGFP: GUU CAG CGU GUC CGG CGA GTT) were
purchased from Hayashi Kasei (Osaka, Japan) and transient
transfection of siRNA oligonucleotide was carried out using
Lipofectamine RNAiMAX (Invitrogen Life Technologies, CA,
USA) according to the manufacturer’s protocol.
Oil red O staining in cardiac myocytes
Neutral lipid within cardiac myocytes was detected by oil red O
staining of fixed cells on gelatin-coated cover slips.
Palmitic acid and glucose oxidation studies
Cellular palmitic acid or glucose oxidation rates were measured as
described previously [38]. In brief, cardiac myocytes were prepared
as above and then plated in approximately equivalent numbers in
T25 flasks. Palmitic acid or vehicle control (Bovine serum albumin;
BSA) exposure began at the switch to serum-free medium 48 h after
Ad-SCD1 or Ad-LacZinfection. Seventeen hours later, the cells were
treated with [
14C]-palmitic acid or [
14C]-glucose (Perkin Elmer, CT,
USA), and #1 Whatman filter paper was suspended within each
flask. The flasks were sealed, and 7 hours later the cells were lysed
with 6N hydrochloric acid. The
14CO2 collected overnight on
Whatman paper was liberated by alkalization with 2N sodium
hydroxide, and was quantified by scintillation counting.
Figure 8. Effect of several humoral factors on SCD1 mRNA
expression in neonatal rat cardiac myocytes. Real-time RT-PCR of
SCD1 expressions in neonatal rat cardiac myocytes stimulated with (A)
angiotensin II (0.1 to 1 mM), endothelin-1 (0.01 to 0.1 mM), norepineph-
rine (1 to 10 mM), lipopolysaccharide (10 to 50 ng/ml) for 24 h, (B)
hypoxia (3 to 9 h) and (C) Hydrogen peroxide (H2O2: 0.1 to 50 mM) for
24 h. High dose (10–50 mM) of hydrogen peroxide significantly
inhibited SCD1 mRNA expression in neonatal rat cardiac myocytes.
Each SCD1 expression is presented relative to the gene expression of
GAPDH and control is normalized to a value of 1. Values are reported as
the means 6 SD. **p,0.01 vs. control.
doi:10.1371/journal.pone.0033283.g008
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Whole cell extracts were prepared using modified RIPA buffer
containing 50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% Nonidet
P-40, 0.25% sodium deoxycholate, 1 mM EDTA, and containing
complete mini and phosSTOP solution (Roche, IN, USA). The
mixture was rotated at 4uC for 15 min and centrifuged at
14000 rpm for 15 min. Western blot analysis was performed
according to standard procedures using the following primary
antibodies: rabbit monoclonal phosphor-AMPK, AMPK, phos-
phor-ACC, ACC, cleaved-caspase 3, caspase 3 mAb (Cell
Signaling) and b-actin (Santa cruz biotechnology, CA, USA).
Antigens were revealed by ECL (Amersham Biosciences, NJ, USA)
after incubation with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit IgG.
DAG and ceramide assay
Intracellular DAG and ceramide levels were measured using a
DAG kinase assay as described previously with slight modification.
Briefly, following 24 h incubation, lipids were extracted by
modification of the method of Bligh and Dyer [35]. Samples
were extracted with 3 ml chloroform/methanol (1:2, v/v).
Sufficient 1 M NaCl was added to bring the aqueous volume to
0.8 ml, and the monophase was mixed. Then, 1 ml CHCl3 and
1 ml of 1 M NaCl were added to the break phase and the phases
were separated by brief centrifugation at 2000 rpm. The
chloroform phase was analyzed within 72 h. Ceramide was
converted to ceramide 1-[
32P] phosphate by E. coli DAG kinase
in the presence of [c-
32P] ATP. Labeled lipids (ceramide-1-
phosphate) were separated by high performance thin-layer
chromatography in chloroform:methanol:water (60:35:8, v/v).
Following autoradiography, spots corresponding to ceramide-1-
phosphate were scraped and radioactivity was counted using a
scintillation counter. Quantification of DAG and ceramide was
based on a standard curve of known amounts of DAG and
ceramide. The changes in DAG and ceramide content were
normalized based on total protein.
Apoptosis assays
For detection of caspase-3 and caspase-7 activation, cardiac
myocytes were plated in replicates of five in 96-well plates,
transfected as described above and analyzed using the Caspase 3/
7 Assay (Promega, WI, USA) according to the manufacturer’s
instructions. Samples were read after 8–24 h of incubation with
the caspase substrate on a fluorescent plate reader.
For labeling nuclei of apoptotic cells, cardiac myocytes were
plated on glass coverslips in 8-well slides, infected, fixed in 4%
paraformaldehyde 48 h post-infection, and terminal deoxynucleo-
tidyl transferase–mediated nick-end labeling (TUNEL) staining
was performed using the In Situ Cell Death Detection Kit,
Fluorescein (Roche) according to the manufacturer’s protocol.
Quantitative ROS detection
Intracellular ROS levels were detected with the oxidant-
sensitive fluorogenic probes 5-(and-6)-chloromethyl-29,79-dichlor-
odihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA,
Invitrogen Life Technologies). Adenovirus infected or siRNA
transfected cardiac myocytes on the 6-well dish were incubated
with 10 mM CM-H2DCFDA in serum-free medium for 30 min at
37uC. Then, the cells were incubated in the presence or absence of
palmitic acid or stearic acid for 20 min. After incubation at 37uC,
fluorescence was detected.
Effect of several humoral factors on SCD1 mRNA
expression
Serum-starved (24 h) cardiac myocytes were incubated in the
presence or absence of angiotensin II (0.1–1 mM), endothelin-1
(0.01–0.1 mM), norepinephrine (1–10 mM), lipopolysaccharide
(10–50 ng/ml), hydrogen peroxide (0.1–50 mM) for 24 h, and
hypoxic stress (3–9 h). After incubation at 37uC, mRNA was
collected from the cells.
Statistical analysis—Values are reported as the mean 6 SD. One
way ANOVA was used to evaluate differences between groups.
Where appropriate, post hoc multiple comparison tests were
Figure 9. A proposed model for the protective role of SCD1 against FA-induced cardiac lipotoxicity. Adaptive stage: SFAs uptake
increases in the myocardium in obesity and diabetes, and SCD1 expression is induced to convert SFAs to MUFAs. Increased SCD1 expression in turn
inhibits FA oxidation and apoptosis through an inhibition of AMPK/ACCb activity and DAG/ceramide synthesis, which protect the heart from lipotoxic
cardiomyopathy. Maladaptive stage: excessive humoral and nutrient stimuli increase oxidative stress which reduces SCD1 expression. As a
consequence, pathways leading to FA oxidation and apoptosis are facilitated and lipotoxic cardiomyopathy occurs.
doi:10.1371/journal.pone.0033283.g009
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experimental groups. A P value ,0.05 was considered significant.
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